Aggressive Differentiated Thyroid Cancer due to EML4e13-ALKe20 Fusion: A Case Presentation and Review of the Literature

Table 1

Prevalence of EML4/ALK fusion.

Author (reference)	Year	Country	Study population	Sample size	Number of persons with kinase gene rearrangement (%)	Patients with EML4/ALK (number)	Findings	Follow-up (months)
Chu et al. [6]	2020	USA	PTC, PDTC, ANC	395	62 (16%)	1	Association seen between kinase gene fusion and clinical aggressiveness	6–480
Hamatani et al. [14]	2012	Japan	Atomic bomb survivors with PTC	105	10 (10%)	6	ALK fusion associated with radiation	NA
Agrawal et al. [15]	2014	USA	Patients with PTC	496	74 (15%)	4	>96% of PTCs have driver oncogenic mutation	NA
Kelly et al. [16]	2014	USA	PTC	256	4 (2%)	1	Compared to EML4-ALK, STRN-ALK is more common in PDTC	NA
Panebianco et al. [17]	2019	USA	PTC and PDTC	44	44 (100%)	17	Compared to EML4-ALK, STRN-ALK is more common in PDTC	2–108 months

PTC = papillary thyroid cancer; ATC = anaplastic thyroid cancer; PDTC = poorly differentiated thyroid cancer.